Erratum: Mimics of the dimerization domain of hepatocyte growth factor exhibit anti-met and anticancer activity (J Pharmacol Exp Ther (2011) 339 (509-518) DOI: 10.1124/jpet.111.185694);Mimics of the dimerization domain of hepatocyte growth factor exhibit anti-met and anticancer activity

Journal of Pharmacology and Experimental Therapeutics

Volumn 339, Issue 2, 2011, Pages 509-518

  Kawas, Leen H ^a   Yamamoto, Brent J ^a   Wright, John W ^a   Harding, Joseph W ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CRK ASSOCIATED SUBSTRATE PROTEIN; METHIONINE; MITOGEN ACTIVATED PROTEIN KINASE; NORLEUAL; P21 ACTIVATED KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SCATTER FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CELL DEATH; CELL MOTILITY; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DIMERIZATION; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; ENZYME INHIBITION; HINGE REGION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; SEQUENCE HOMOLOGY; WESTERN BLOTTING;

EID: 80054788430     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.185694concern     Document Type: Erratum

References (40)

1. Accornero P, Pavone LM, and Baratta M (2010) The scatter factor signaling pathways as therapeutic associated target in cancer treatment. Curr Med Chem 17: 2699-2712.
2. Birchmeier C, Birchmeier W, Gherardi E, and Vande Woude GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915-925. (Pubitemid 37493640)
3. Burgess T, Coxon A, Meyer S, Sun J, Rex K, Tsuruda T, Chen Q, Ho SY, Li L, Kaufman S, et al. (2006) Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Metdependent human tumors. Cancer Res 66:1721-1729. (Pubitemid 43259957)
4. Cañadas I, Rojo F, Arumí-Uría M, Rovira A, Albanell J, and Arriola E (2010) C-MET as a new therapeutic target for the development of novel anticancer drugs. Clin Transl Oncol 12:253-260.
5. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, Chen J, Wang X, Ruslim L, Blake R, et al. (2003) A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 63:7345-7355. (Pubitemid 37413476)
6. Comoglio PM and Boccaccio C (2001) Scatter factors and invasive growth. Semin Cancer Biol 11:153-165. (Pubitemid 32423290)
7. Cramer T, Schuppan D, Bauer M, Pfander D, Neuhaus P, and Herbst H (2004) Hepatocyte growth factor and c-Met expression in rat and human liver fibrosis. Liver Int 24:335-344. (Pubitemid 39172060)
8. Danilkovitch-Miagkova A and Zbar B (2002) Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest 109:863-867. (Pubitemid 34275106)
9. Derksen PW, de Gorter DJ, Meijer HP, Bende RJ, van Dijk M, Lokhorst HM, Bloem AC, Spaargaren M, and Pals ST (2003) The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia 17:764-774. (Pubitemid 36519374)
10. Ferraro D, Corso S, Fasano E, Panieri E, Santangelo R, Borrello S, Giordano S, Pani G, and Galeotti T (2006) Pro-metastatic signaling by c-Met through RAC-1 and reactive oxygen species (ROS). Oncogene 25:3689-3698. (Pubitemid 43980490)
11. Gentile A, Trusolino L, and Comoglio PM (2008) The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev 27:85-94.
12. Gherardi E, Sandin S, Petoukhov MV, Finch J, Youles ME, Ofverstedt LG, Miguel RN, Blundell TL, Vande Woude GF, Skoglund U, et al. (2006) Structural basis of hepatocyte growth factor/scatter factor and MET signalling. Proc Natl Acad Sci USA 103:4046-4051.
13. Halaban R, Rubin JS, Funasaka Y, Cobb M, Boulton T, Faletto D, Rosen E, Chan A, Yoko K, and White W (1992) Met and hepatocyte growth factor/scatter factor signal transduction in normal melanocytes and melanoma cells. Oncogene 7:2195-2206.
14. Hansel TT, Kropshofer H, Singer T, Mitchell JA, and George AJ (2010) The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 9:325-338.
15. Kakazu A, Chandrasekher G, and Bazan HE (2004) HGF protects corneal epithelial cells from apoptosis by the PI-3K/Akt-1/Bad- but not the ERK1/2-mediated signaling pathway. Invest Ophthalmol Vis Sci 45:3485-3492. (Pubitemid 39298566)
16. Kanda S, Kanetake H, and Miyata Y (2006) HGF-induced capillary morphogenesis of endothelial cells is regulated by Src. Biochem Biophys Res Commun 344:617-622.
17. Kopp JB (1998) Hepatocyte growth factor: mesenchymal signal for epithelial homeostasis. Kidney Int 54:1392-1393.
18. Kuba K, Matsumoto K, Date K, Shimura H, Tanaka M, and Nakamura T (2000) HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res 60:6737-6743.
19. Liu X, Newton RC, and Scherle PA (2010) Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med 16:37-45.
20. Liu X, Yao W, Newton RC, and Scherle PA (2008) Targeting the c-MET signaling pathway for cancer therapy. Expert Opin Investig Drugs 17:997-1011.
21. Lodish MB and Stratakis CA (2010) Endocrine side effects of broad-acting kinase inhibitors. Endocr Relat Cancer 17:R233-R244.
22. Maina F and Klein R (1999) Hepatocyte growth factor, a versatile signal for developing neurons. Nat Neurosci 2:213-217. (Pubitemid 30491290)
23. Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, Westphal M, and Lamszus K (2006) A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 12:6144-6152. (Pubitemid 44703780)
24. Matsumoto K and Nakamura T (2008) NK4 gene therapy targeting HGF-Met and angiogenesis. Front Biosci 13:1943-1951. (Pubitemid 351599746)
25. Michieli P, Mazzone M, Basilico C, Cavassa S, Sottile A, Naldini L, and Comoglio PM (2004) Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 6:61-73. (Pubitemid 38903162)
26. Morotti A, Mila S, Accornero P, Tagliabue E, and Ponzetto C (2002) K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene 21:4885-4893.
27. Ratajczak MZ, Marlicz W, Ratajczak J, Wasik M, Machalinski B, Carter A, and Gewirtz AM (1997) Effect of hepatocyte growth factor on early human haemopoietic cell development. Br J Haematol 99:228-236. (Pubitemid 27461354)
28. Sakkab D, Lewitzky M, Posern G, Schaeper U, Sachs M, Birchmeier W, and Feller SM (2000) Signaling of hepatocyte growth factor/scatter factor (HGF) to the small GTPase Rap1 via the large docking protein Gab1 and the adapter protein CRKL. J Biol Chem 275:10772-10778. (Pubitemid 30212706)
29. Sattler M, Pride YB, Ma P, Gramlich JL, Chu SC, Quinnan LA, Shirazian S, Liang C, Podar K, Christensen JG, et al. (2003) A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res 63:5462-5469. (Pubitemid 37139865)
30. Sengupta S, Gherardi E, Sellers LA, Wood JM, Sasisekharan R, and Fan TP (2003) Hepatocyte growth factor/scatter factor can induce angiogenesis independently of vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 23:69-75. (Pubitemid 36091628)
31. Stabile LP, Rothstein ME, Keohavong P, Jin J, Yin J, Land SR, Dacic S, Luong TM, Kim KJ, Dulak AM, et al. (2008) Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis. Mol Cancer Ther 7:1913-1922.
32. Stella MC and Comoglio PM (1999) HGF: a multifunctional growth factor controlling cell scattering. Int J Biochem Cell Biol 31:1357-1362.
33. Takayama H, LaRochelle WJ, Sharp R, Otsuka T, Kriebel P, Anver M, Aaronson SA, and Merlino G (1997) Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci USA 94:701-706.
34. Thompson J, Dolcet X, Hilton M, Tolcos M, and Davies AM (2004) HGF promotes survival and growth of maturing sympathetic neurons by PI-3 kinase- and MAP kinase-dependent mechanisms. Mol Cell Neurosci 27:441-452. (Pubitemid 39539998)
35. Weidner KM, Di Cesare S, Sachs M, Brinkmann V, Behrens J, and Birchmeier W (1996) Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature 384:173-176. (Pubitemid 26386473)
36. Yamamoto BJ, Elias PD, Masino JA, Hudson BD, McCoy AT, Anderson ZJ, Varnum MD, Sardinia MF, Wright JW, and Harding JW (2010) The angiotensin IV analog Nle-Tyr-Leu-ψ(CH2-NH2)3-4-His-Pro-Phe (norleual) can act as a hepatocyte growth factor/c-Met inhibitor. J Pharmacol Exp Ther 333:161.
37. Youles M, Holmes O, Petoukhov MV, Nessen MA, Stivala S, Svergun DI, and Gherardi E (2008) Engineering the NK1 fragment of hepatocyte growth factor/ scatter factor as a MET receptor antagonist. J Mol Biol 377:616-622.
38. Zeng Q, McCauley LK, and Wang CY (2002) Hepatocyte growth factor inhibits anoikis by induction of activator protein 1-dependent cyclooxygenase-2. Implication in head and neck squamous cell carcinoma progression. J Biol Chem 277: 50137-50142. (Pubitemid 36014467)
39. Zhang YW, Su Y, Volpert OV, and Vande Woude GF (2003) Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci USA 100:12718-12723. (Pubitemid 37339965)
40. Zhang YW and Vande Woude GF (2003) HGF/SF-met signaling in the control of branching morphogenesis and invasion. J Cell Biochem 88:408-417.